

February 5, 2019



# Intensity Therapeutics to Participate in Panel at 2019 BIO CEO & Investor Conference

WESTPORT, Conn., Feb. 05, 2019 (GLOBE NEWSWIRE) -- [Intensity Therapeutics, Inc.](http://www.intensitytherapeutics.com), a clinical-stage biotechnology company developing proprietary technology and products to kill tumors and increase immune cell recognition of solid tumor cancers, today announced that Lewis H. Bender, President and CEO, will participate in the "Reshaping Tumor Microenvironments via Immunotherapies" [panel](#) at the 2019 BIO CEO & Investor Conference. The panel will examine the next wave of innovation in immunotherapies, leveraging knowledge of how tumor microenvironments develop to create treatments able to demonstrate more durable effects on shrinking tumors across wider ranges of patients. The panel will be held on Monday, February 11, 2019 at 9:00 a.m. ET in New York, NY.

## About Intensity Therapeutics

Intensity Therapeutics, Inc. is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. Intensity leverages its DfuseRx<sup>SM</sup> technology platform to create new drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive immune response that not only attacks the injected tumor, but also non-injected tumors and unseen micro-metastases. INT230-6, Intensity's lead product candidate, is being evaluated in a Phase 1/2 clinical study in patients with various advanced solid tumors. For more information, please visit [www.intensitytherapeutics.com](http://www.intensitytherapeutics.com) and follow us on Twitter [@IntensityInc](https://twitter.com/IntensityInc).

## Forward Looking Statements

*This press release contains forward-looking statements regarding Intensity Therapeutics' plans, future operations and objectives. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual performance or achievements to be materially different from those currently anticipated. These forward-looking statements include, among other things, statements about the initiation and timing of future clinical trials.*

## Contacts

Investors:

Kerry Conlin

Stern Investor Relations

212-698-8685

[kerry.conlin@sternir.com](mailto:kerry.conlin@sternir.com)

Media:

Tony Plohoros

6 Degrees PR

(908) 591-2839

[tplohoros@6degreespr.com](mailto:tplohoros@6degreespr.com)



Source: Intensity Therapeutics Inc